Clinical Trials
2
Active:2
Completed:0
Trial Phases
1 Phases
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 2
1 (100.0%)Phase 2 Study on the Pharmacokinetics and Safety of RLYB212 in Pregnant Women at Higher Risk for HPA-1a Alloimmunization
Phase 2
Active, not recruiting
- Conditions
- Fetal and Neonatal Alloimmune Thrombocytopenia
- Interventions
- Drug: Anti-(integrin beta-3) human monoclonal antibody
- First Posted Date
- 2024-05-30
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Rallybio
- Target Recruit Count
- 8
- Registration Number
- NCT06435845
- Locations
- 🇳🇱
Leids Universitair Medisch Centrum, Leiden, Zuid-Holland, Netherlands
🇳🇴Oslo University Hospital- Ullevål, Oslo, Norway
🇸🇪Södersjukhuset, Stockholm, Sweden
Study to Assess the Occurrence of HPA-1a Alloimmunization in Women With Higher Risk for Fetal and Neonatal Alloimmune Thrombocytopenia
Active, not recruiting
- Conditions
- Fetal and Neonatal Alloimmune Thrombocytopenia
- First Posted Date
- 2022-04-26
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Rallybio
- Target Recruit Count
- 30000
- Registration Number
- NCT05345561
- Locations
- 🇺🇸
New Horizons Clinical Trials, LLC, Chandler, Arizona, United States
🇺🇸Zillan Clinical Research - Gardena, Gardena, California, United States
🇺🇸Yale University School of Medicine, New Haven, Connecticut, United States
News
No news found